Clinical trials: Diabetes Mellitus Type 2 (T2DM)
Chronic Kidney Disease(CKD), Type 2 DM
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Conditions
- Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- IRIS-CKD (NCT06906640)
- Testing
- (IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
- Where
- 7 sites in United States
- Volunteers
- 212 people
- Sponsor
- Duke University
Type 2 Diabetes
A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will comprise a randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT07065032
- Testing
- ZT002 Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes
The purpose of Part A of this study is to test whether repeated doses of the study drug (GSK1614235) are safe and well tolerated (i.e.
- Trial name
- SGA112534 (NCT00976261)
- Testing
- GSK1614235, Sitagliptin
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients.
- Trial name
- SPOTLIGHT (NCT07456774)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Congestive Heart Failure, Type II Diabetes Mellitus
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III).
- Trial name
- NCT00894868
- Testing
- vildagliptin
- Where
- 93 sites in Czechia, Denmark and 13 more
- Volunteers
- 798 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Purpose This study will examine the effect of the addition of Cycloset upon glucose metabolism (glycemic control including post prandial glucose metabolism) in individuals with inadequately controlled (HbA1c 7.5-10.0) type 2…
- Trial name
- NCT02299050
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
T2DM (Type 2 Diabetes Mellitus)
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
- Trial name
- NCT04632862
- Testing
- DWP16001
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
To investigate whether single administration of sitaglitpin can restore acute endothelial dysfunction and ameliorate impaired increase of the number of endothelial progenitor cells (EPCs) after oral glucose loading in patients…
- Trial name
- NCT02301806
- Testing
- dieting, Sitagliptin, Glimepiride
- Where
- 2 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Dokkyo Medical University
Diabetes Mellitus, Type 2
Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters (PSV, EDV, RI) of Retrobulbar Blood Vessels (CRA, PCA, and OA) in 48 T2DM Patients Did Not Combinate With DR
Objective: The main target of this study was to research the correlation between the pulmonary function and the circulatory parameters of retrobulbar blood vessels in patients with type 2 diabetes (T2DM) without diabetic…
- Trial name
- CPCT2DM (NCT02774733)
- Testing
- spirometer;Intraocular pressure;Color doppler imaging
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fourth People's Hospital of Shenyang
Type 2 Diabetes (T2DM)
The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
The goal of this clinical trial is to to study the effect of Optifiber PHGG on carbohydrate metabolism in patients with type 2 diabetes mellitus. The main questions it aims to answer are: 1.
- Trial name
- NCT07609992
- Testing
- Nestle Optifibre
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pirogov Russian National Research Medical University
Type 2 Diabetes Mellitus (T2DM), Sleep
Physical Activity Level and Sleep Quality in Type 2 Diabetes
In this study, we investigated the effects of physical activity level and sleep quality level on total antioxidant level (TAS), total oxidant level (TOS), Malondialdehyde (MDA) and Superoxide Dismutase (SOD) which are markers of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sleep, Biomarkers / Blood, Physical Activity Level
- Trial name
- NCT06602778
- Testing
- Biomarkers / blood, Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Selcuk University
Diabetes Mellitus, Type 2, Healthy Volunteers
A Study of Dulaglutide in Chinese Participants
This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body.
- Trial name
- NCT01667900
- Testing
- Dulaglutide
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type II Diabetes Mellitus
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM
This is a non-interventional, cross sectional, multicentric study in T2DM patients which will involve a single visit for study related procedures.
- Trial name
- INSIGHT (NCT01523405)
- Where
- 70 sites in India
- Volunteers
- 4,911 people
- Sponsor
- AstraZeneca
T2DM (Type 2 Diabetes Mellitus)
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
This study is a multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study aimed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SYH2069 Injection in…
- Trial name
- NCT07796477
- Testing
- SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a…
- Trial name
- NCT03951753
- Testing
- Tirzepatide, Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type II
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
- Trial name
- NCT00947557
- Testing
- Dutogliptin
- Where
- 147 sites in United States, Belarus and 6 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes Mellitus
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on…
- Trial name
- NCT02226003
- Testing
- Ertugliflozin, Sitagliptin, Glimepiride
- Volunteers
- 291 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
The primary objective of this study is to determine the effect of maridebart cafraglutide relative to placebo on insulin sensitivity in participants with Type 2 Diabetes Mellitus (T2DM) treated with stable dose of metformin.
- Trial name
- NCT07160257
- Testing
- Maridebart cafraglutide
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Amgen